Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
23 shown of 6,779 total abstracts
  1. Abstract 62712026-06-02 · 20:15 CT · Hall B1
    CheckMate-815: Opdivo (nivolumab) adjuvant in RCC
    S. Antonia, E. Winer, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 64172026-06-02 · 13:00 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-364
    R. Herbst, S. Antonia, C. Robert · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 64682026-06-02 · 20:45 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-472
    P. Schmid, H. Borghaei, M. Reck, et al. · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 61852026-06-02 · 13:30 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with RCC
    L. Paz-Ares, A. Spira, M. Krop · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 68102026-06-03 · 20:15 CT · E450
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-527
    S. Peters, M.C. Garassino, H. Rugo, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 68712026-06-05 · 13:45 CT · Hall B1
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-211
    S. Antonia, M. Reck, J. Brahmer · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 64512026-06-05 · 19:15 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in RCC
    M. Reck, J. Brahmer, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 68532026-06-05 · 16:15 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-793
    F. Andre, S. Tolaney, H. Borghaei, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 65502026-06-05 · 18:30 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M. Reck, F. Andre · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract 61752026-06-01 · 20:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-430 study)
    J. Brahmer, H. Borghaei, F. Andre, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  11. Abstract 61432026-06-03 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-824
    C. Robert, C. Saura · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 65332026-06-01 · 21:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-591
    S. Antonia, M. Krop, R. Herbst, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 64892026-06-03 · 21:45 CT · Arie Crown Theater
    KEYNOTE-165: Keytruda (pembrolizumab) 2L in RCC
    S. Antonia, C. Saura, S. Modi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 62362026-06-03 · 18:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-758
    A. Spira, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  15. Abstract 67592026-06-04 · 16:45 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-264 study)
    P. Schmid, S. Tolaney, A. Spira · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 66862026-06-03 · 14:30 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-226 study)
    S. Peters, E. Winer · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 62122026-06-01 · 15:00 CT · E450
    Quality of life outcomes with Keytruda in patients with RCC
    E. Winer, R. Herbst, M. Krop · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  18. Abstract 60982026-06-02 · 21:45 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-608 study)
    J. Brahmer, R. Herbst, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 67412026-06-03 · 19:15 CT · Hall B1
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-533
    M. Krop, R. Herbst, S. Antonia, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract 68582026-06-02 · 15:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-261
    L. Paz-Ares, S. Antonia, S. Modi · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 68502026-06-03 · 19:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-901 study)
    S. Modi, S. Antonia, F. Andre · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 69042026-06-05 · 20:00 CT · Arie Crown Theater
    KEYNOTE-140: Keytruda (pembrolizumab) neoadjuvant in RCC
    L. Paz-Ares, M.C. Garassino, E. Winer · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  23. Abstract 66152026-06-04 · 18:30 CT · Hall B1
    KEYNOTE-994: Keytruda (pembrolizumab) 3L+ in RCC
    C. Robert, S. Peters, H. Borghaei, et al. · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.